Literature DB >> 3063174

Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic.

R S Gordee1, D J Zeckner, L C Howard, W E Alborn, M Debono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3063174     DOI： 10.1111/j.1749-6632.1988.tb40415.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  22 in total

Review 1.  Antifungal peptides: novel therapeutic compounds against emerging pathogens.

Authors:  A J De Lucca; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Comparison of cilofungin and amphotericin B for therapy of murine candidiasis.

Authors:  K R Smith; K M Lank; C G Cobbs; G A Cloud; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

5.  Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  V Petraitis; R Petraitiene; A H Groll; A Bell; D P Callender; T Sein; R L Schaufele; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

6.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis.

Authors:  M B Kurtz; C Douglas; J Marrinan; K Nollstadt; J Onishi; S Dreikorn; J Milligan; S Mandala; J Thompson; J M Balkovec
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

8.  Use of cilofungin as direct fluorescent probe for monitoring antifungal drug-membrane interaction.

Authors:  Y T Ko; R D Ludescher; D J Frost; B P Wasserman
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.

Authors:  K R Smith; K M Lank; W E Dismukes; C G Cobbs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

10.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.